Bioject Announces Roche and Trimeris Update on the Use of Fuzeon(R) with Biojector(R) 2000.

PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems today announced that it has been notified by Roche and Trimeris that they will not be proceeding with their FDA submission for Fuzeon[R] to be administered with the Biojector[R] 2000 ("B2000").

"We would have preferred to see the process completed and to have been able to provide the B2000 to all HIV patients," said Ralph Makar, President and Chief Executive Officer of Bioject. "Our device offers benefits over the use of needle and syringe for the delivery of injectables, as millions of injections have been administered by the B2000 since its release by the FDA in 1993. We continue to pursue other opportunities with current and new partners for its use in benefiting patients."

"We are pleased that patients who are currently delivering Fuzeon with the B2000 through existing programs and clinical trials may continue to do so," said Dr. Richard Stout, Executive Vice President and Chief Medical Officer. "We realize the need for alternatives to the needle and syringe to reduce injection site reaction as suggested in the clinical trials and we look forward to learning more from the on-going clinical trials."

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information on Bioject, visit www.bioject.com.